Muscle homeostasis is maintained by resident stem cells which, in both pathologic and non-pathologic conditions, are able to repair or generate new muscle fibers. Although muscle stem cells have tremendous regenerative potential, their application in cell therapy protocols is prevented by several restrictions, including the limited ability to grow ex vivo. Since pluripotent stem cells have the unique potential to both selfrenew and expand almost indefinitely, they have become an attractive source of progenitors for regenerative medicine studies. Our lab has demonstrated that embryonic stem cell (ES)-derived myogenic progenitors retain the ability to repair existing muscle fibers and contribute to the pool of resident stem cells. Because of their relevance in both cell therapy and disease modeling, in this chapter we describe the protocol to derive myogenic progenitors from murine ES cells followed by their intramuscular delivery in a murine muscular dystrophy model.
|Original language||English (US)|
|Title of host publication||Methods in Molecular Biology|
|Publisher||Humana Press Inc.|
|Number of pages||18|
|State||Published - 2016|
|Name||Methods in Molecular Biology|
Bibliographical noteFunding Information:
The Perlingeiro laboratory is supported by grants from the NIH (R01 AR055299), the Muscular Dystrophy Association (MDA #238127) and Parent Project Muscular Dystrophy (PPMD #00031645). A.M. was funded by a fellowship from Regenerative Medicine Minnesota (MRM 2015 PDSCH 003).
© Springer Science+Business Media New York 2016.
- Cell therapy
- ES and iPS cells
- Muscle differentiation
- Myogenic progenitors
- Skeletal muscle